Comparison of efficacy of high dose inhaled corticosteroids with a combination of low dose inhaled corticosteroids and long acting β2 agonists in patients of moderate persistent asthma : a randomised prospective comparative study

Vivek Sood, Parveen Sharma, Rekha Bansal, Dinesh Kansal


Background: Asthma has global prevalence varying from 2-25%. Among various subtypes, moderate persistent asthma is a subtype currently managed by a combination therapy of low dose inhaled corticosteroids and LABA (long acting β2 agonists). Search is on for LABA free regime because of safety concerns and increased risk of exacerbations as reported in meta-analysis conducted by FDA in 2008.

Methods: Patients (new and old) of either sex and age having moderate persistent asthma as per GINA 2004 guidelines were enrolled and allocated in two groups using block randomization. DPIs (dry powder inhalation) were used in the study. Budecort group subjects were treated with budesonide 400 µg rotacaps twice a day. Foracort group subjects were treated with combination rotacaps of formoterol 6 µg with budesonide 200 µg twice a day. Follow up period in study was nine months with quarterly spirometry assessment.

Results: In 63 enrolled cases, there was no significant difference in intergroup spirometry comparison at baseline and at 9 months. The difference at 9 months in spirometry as compared from baseline in each group was also not statistically significant. Numerically, budecort group showed slightly better values.

Conclusions: The therapy in each group was comparable in terms of efficacy. This is important due to the fact that therapy in current use for moderate persistent asthma is combination therapy. So use of high dose inhaled steroid therapy used as 400 µg rotacaps with matching revolizer twice a day (800µg daily) may be good alternative to use of combination therapy particularly in patients where LABA cannot be used.


Asthma treatment, Moderate persistent asthma treatment, High dose steroids in asthma, Combination therapy in asthma, Long acting β2 agonists, Dry powder inhalation use

Full Text:



Guy M, Neil P, David S, Innes A. Global burden of disease due to asthma. The Global Asthma Report 2014. Available at. http://www.globalasthma report. org/ burden/burden.php. Accessed 5 January 2016.

Shah JR, Amdekar YK, Mathur RS. Nationwide variation in prevalence of bronchial asthma (part of the international study of asthma and allergies in childhood-ISAAC). Indian J Med Sci. 2000;54:213-20.

Asthma Risk Factors. lung health and diseases. Available at. asthma-symptoms-causes-risk-factors/asthma-risk-factors.html. Accessed 5 January 2016.

WHO. Asthma: definition. Available at. asthma/definition/en. Accessed 20 March 2014.

Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respiratory medicine. 2006;100:1307-17.

Rossi G, Cerasoli F, Cazzola M. Safety of inhaled corticosteroids: room for improvement. Pulmonary pharmacology and therapeutics. 2007;20:23-35.

Rang HP, Rang HP, Dale MM, Ritter JM, Flower R, Henderson G. Editors. Pulmonary disease and its treatment. In: Rang and Dale’s Pharmacology. 7th ed. Elsevier; 2010:336-46.

Wijesinghe M, Perrin K, Harwood M, Weatherall M, Beasley R. The risk of asthma mortality with inhaled long acting beta-agonists. Postgrad Med Journal. 2008;84:467-72.

Foster C. Asthma treatment. In: Cooper D, Neville Mistry N, Peddi PF, Sharma S. Editors. Washington manual of medical therapeutics. 32nd ed. Lippincott Williams and Wilkins; 2010:306.

Rodrigo GJ, Castro-Rodríguez JA. Safety of long-acting β agonists for the treatment of asthma: clearing the air. Thorax. 2012;67(4):342-9.

Weir NA, Levine SJ. Achieving symptom control in patients with moderate asthma. Clin Med Insights Circ Respir Pulm Med. 2012;6:1-11.